InvestorsHub Logo
Followers 129
Posts 23648
Boards Moderated 1
Alias Born 09/14/2016

Re: None

Friday, 03/22/2019 1:05:21 PM

Friday, March 22, 2019 1:05:21 PM

Post# of 3159
Q BioMed (QBIO) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investors might expect, this kit offers the potential to improve the quality of life for glaucoma sufferers by helping preserve visual function in glaucoma patients through accurate monitoring of disease progression. As a result, this diagnostic offers substantial future value to the Company. https://finance.yahoo.com/news/q-biomeds-industry-changing-diagnostic-113000799.html